Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Articles|September 8, 2010
Read Between the Lines
When a patient complains of a “sore that won’t heal” or mentions that a lesion “constantly bleeds and scabs,” heed the advice of Osler.
Advertisement
When a patient complains of a "sore that won't heal" or mentions that a lesion "constantly bleeds and scabs," heed the advice of Osler: "Listen to the patient, he is telling you the diagnosis." This characteristic description best fits the diagnosis of a basal cell carcinoma.
--
Benjamin Barankin, MD
Toronto
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5